Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans

ABSTRACT: A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans

PROVIDER: PRJNA633581 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans

Project description:Dermatofibrosarcoma protuberans (DFSP) is a soft-tissue sarcoma characterized by a high risk of local infiltration. The identification of the COL1A1-PDGFB t(17;22) translocation activating the PDGF pathway led to the use of imatinib in unresectable DFSP, with a response rate of 36-80%. Pazopanib is a multitarget tyrosine kinase inhibitor approved for soft tissue sarcomas. We conducted a phase II study of patients with unresectable DFSP to evaluate the efficacy and safety of pazopanib. Patients received 800 mg pazopanib daily. The primary endpoint was the objective response rate defined as the reduction of the largest diameter of the tumor ≥30% at 6 months or at surgery assessed by physical examination. Twenty-three patients, including one pre-treated with imatinib, were enrolled. With a median follow-up of 6.2 months (interquartile range 5.6-7.8 months), 5 patients (22%, 95% CI: 7-22%) had a partial response to pazopanib. The best objective response rate was 30% (95% CI 13-53%) using RECIST. One patient with metastatic DFSP previously treated with imatinib died after 2.4 months. Nine (39%) patients discontinued the treatment due to adverse events. Pharmacodynamics analyses of tumor samples were conducted: the enrichment of EGF and the EGFR-associated gene panel was associated with resistance, suggesting that EGFR-targeted therapies could be a therapeutic option to explore in DFSP.

2020-05-19 | GSE150787 | GEO

Multicenter AIDS Cohort Study

Project description:Multicenter AIDS Cohort Study

| PRJNA671263 | ENA

Multicenter AIDS Cohort Study

Project description:Multicenter AIDS Cohort Study

| PRJNA671262 | ENA

A091401 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma

Project description:A091401 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma

| PRJNA1164329 | ENA

A091401 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma

Project description:A091401 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma

| PRJNA1164328 | ENA

Phase 2 study of Nivolumab and Entinostat in unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma

Project description:Phase 2 study of Nivolumab and Entinostat in unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma

| PRJNA1102448 | ENA

Phase 2 study of Nivolumab and Entinostat in unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma

Project description:Phase 2 study of Nivolumab and Entinostat in unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma

| PRJNA1102449 | ENA

Multicenter Study of Hydroxyurea (MSH)

Project description:Multicenter Study of Hydroxyurea (MSH)

| PRJNA701326 | ENA

Multicenter Study of Hydroxyurea (MSH)

Project description:Multicenter Study of Hydroxyurea (MSH)

| PRJNA701327 | ENA

A lncRNA HAR1B has a potential as a predictive marker for pazopanib therapy in patients with sarcoma

Project description:Bone and soft tissue sarcomas are rare and highly heterogeneous mesenchymal malignancies. Their rarity makes it difficult to acquire clinical data of patients with specific histological subtypes of sarcoma from large clinical trials. The diagnoses and treatment of sarcomas need to be further developed. We show that a long non-coding RNA (lncRNA) HAR1B may serve as predictive biomarkers for pazopanib treatment in bone and soft tissue sarcomas. Multiplex real-time reverse transcription polymerase chain reaction and microarray analyses revealed that HAR1B and HOTAIR were differentially expressed in pazopanib-sensitive cells and responders. We further clarified this mechanism by showing that siRNA-knockdown of HAR1B led to an increased resistance to pazopanib in sarcoma cell lines. Gene expression profiles related to pazopanib sensitivity included cellular molecular pathways, including genes involved in von-Willebrand factor-related signaling. Our study demonstrates that lncRNA HAR1B expression affects cellular sensitivity to pazopanib in sarcoma cell lines and in patients with sarcoma.

2021-04-28 | GSE156344 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data